RESEARCHER PROFILE
Dr Erin Brazel
University of Adelaide
Filmed February 2024
Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.
The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.
The fellowship will support research on bacterial vaccines in a joint GPN Vaccines Ltd and the University of Adelaide project to explore combination vaccines for ear infections using Gamma-PN.
Bacterial ear infections are the most common bacterial disease affecting children. In Australia, episodes range from 1-2.4 million each year, affecting over 600,000 individuals, with 40% of these children experiencing six or more recurrences before the age of eight. Persistent cases can result in hearing loss and learning difficulties, leading to developmental delays and impacts on psychosocial health. Chronic ear infections have also been linked to increased rates of obesity during childhood and Later in life, which may be a result of prolonged antibiotic usage.
With antibiotic resistant superbugs projected to kill 10 million people each year by 2050, new ways of combatting disease are urgently required. A major focus of Dr Brazel’s research is the development of new vaccines to address emerging and existing pathogens that threaten global health and biosecurity. Vaccines are an important tool for reducing disease caused by antimicrobial resistant pathogens, the spread of resistant bacteria, and to reduce antimicrobial use in health and animal care.
Dr Brazel has contributed to the design and preclinical testing of many next generation vaccine candidates, including the current lead candidate (Gamma-PN3). This vaccine is currently being tested in a first-in-human Phase 1 clinical trial (commenced January 2023).
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
